Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.37 |
| ▸ | PRKDC | P78527 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | BCR | P11274 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26548686 | 1.00 | CREBBP (0.37) | CREBBPPRKDCFGFR1FGFR2FGFR3 | |
| SCHEMBL24316696 | 0.87 | FGFR1 (0.43) | CREBBPFGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL29471176 | 0.87 | FGFR1 (0.43) | CREBBPFGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL24316544 | 0.86 | CREBBP (0.35) | CREBBPFGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL29471227 | 0.85 | FGFR1 (0.37) | CREBBPPRKDCFGFR1FGFR2FGFR3 | |
| SCHEMBL24316636 | 0.85 | FGFR1 (0.37) | CREBBPPRKDCFGFR1FGFR2FGFR3 | |
| SCHEMBL24316725 | 0.85 | FGFR4 (0.35) | CREBBPPRKDCFGFR1FGFR2FGFR3 | |
| SCHEMBL29471151 | 0.82 | CREBBP (0.36) | CREBBPPRKDCFGFR1FGFR2FGFR3 | |
| SCHEMBL24316886 | 0.82 | CREBBP (0.36) | CREBBPPRKDCFGFR1FGFR2FGFR3 | |
| SCHEMBL24316641 | 0.81 | CSF1R (0.33) | CREBBPFGFR1FGFR2FGFR3FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210683-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | Aurigene Oncology Limited (IN) | 2023-07-19 | — | — | EP | disclosed |
| CN-116368128-A | Heterocyclic compounds as CBP/EP300 bromodomain inhibitors | 奥瑞基尼肿瘤有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |